TABLE 3.
Factors associated with SARS‐CoV‐2 infection among people living with HIV (PLWH)
| p Value | ||||
|---|---|---|---|---|
| Parameter | SARS‐CoV‐2 infection n (%) | Bivariate | Multivariable | Incidence rate ratio (95% CI) † |
| Sex | .563 | .877 | 1.1 (0.47–2.41) | |
| Male | 46 (8) | |||
| Female | 9 (6.6) | |||
| Age | .319 | .183 | 0.98 (0.96–1.01) ‡ | |
| <52 years | 30 (8.8) | |||
| ≥52 years | 25 (6.8) | |||
| Risk factor for HIV infection | .008 | .367 | 1.37 (0.69–2.73) | |
| MSM | 29 (11.3) | |||
| Non‐MSM | 26 (5.8) | |||
| Active tobacco use | <.001 | <.001 | 0.29 (0.16–0.55) | |
| Yes | 14 (3.8) | |||
| No | 41 (12.3) | |||
| Alcohol intake | .278 | ‐ | ‐ | |
| Abstinent | 30 (8.9) | |||
| Non‐abstinent | 25 (6.7) | |||
| Active opiate use | ||||
| Yes | 3 (6.3) | 1.000 | ‐ | ‐ |
| No | 52 (7.9) | |||
| CDC stage | .118 | .485 | 1.25 (0.67–2.33) | |
| A | 37 (9.1) | |||
| B or C | 18 (5.9) | |||
| CD4 nadir cell count | .488 | ‐ | ||
| <200 cell/ml | 19 (7.0) | ‐ | ||
| ≥200 cell/ml | 28 (8.5) | |||
| Baseline plasma HIV viral load | .216 | ‐ | ‐ | |
| <50 copies/ml | 53 (8.2) | |||
| ≥50 copies/ml | 2 (3.2) | |||
| TDF or TAF/FTC backbone | .727 | ‐ | ‐ | |
| Yes | 28 (8.3) | |||
| No | 27 (7.3) | |||
| Charlson index | ‐ | ‐ | ||
| ≤2 | 40 (7.9) | .830 | ||
| >2 | 15 (7.4) | |||
Abbreviations: FTC, emtricitabine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
†
95% confidence interval.
‡
Entered as continuous variable in the multivariable analysis.
§
Available data for 601 patients.